JP Morgan Chase’s Marker Therapeutics MRKR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $25 | Hold |
23
| – | – | ﹤0.01% | 7963 |
|
|
2026
Q2 | $34 | Hold |
23
| – | – | ﹤0.01% | 7606 |
|
|
2026
Q1 | $29 | Hold |
23
| – | – | ﹤0.01% | 7392 |
|
|
2025
Q4 | $34 | Hold |
23
| – | – | ﹤0.01% | 7271 |
|
|
2025
Q3 | $21 | Sell |
23
-192
| -89% | -$237 | ﹤0.01% | 7283 |
|
|
2025
Q2 | $329 | Buy |
215
+179
| +497% | +$230 | ﹤0.01% | 6742 |
|
|
2025
Q1 | $44 | Sell |
36
-2
| -5% | -$4 | ﹤0.01% | 7004 |
|
|
2024
Q4 | $119 | Hold |
38
| – | – | ﹤0.01% | 6984 |
|
|
2024
Q3 | $107 | Hold |
38
| – | – | ﹤0.01% | 6992 |
|
|
2024
Q2 | $206 | Hold |
38
| – | – | ﹤0.01% | 6782 |
|
|
2024
Q1 | $164 | Buy |
38
+5
| +15% | +$22 | ﹤0.01% | 6833 |
|
|
2023
Q4 | $182 | Sell |
33
-801
| -96% | -$2.72K | ﹤0.01% | 7061 |
|
|
2023
Q3 | $3.84K | Buy |
834
+711
| +578% | +$3.97K | ﹤0.01% | 6416 |
|
|
2023
Q2 | $381 | Hold |
123
| – | – | ﹤0.01% | 6567 |
|
|
2023
Q1 | $0 | Sell |
123
-1
| -0.8% | -$2 | ﹤0.01% | 7044 |
|
|
2022
Q4 | $0 | Sell |
124
-5
| -4% | -$17 | ﹤0.01% | 6825 |
|
|
2022
Q3 | $0 | Buy |
129
+5
| +4% | +$18 | ﹤0.01% | 6707 |
|
|
2022
Q2 | $0 | Hold |
124
| – | – | ﹤0.01% | 6723 |
|
|
2022
Q1 | $0 | Hold |
124
| – | – | ﹤0.01% | 6859 |
|
|
2021
Q4 | $1K | Hold |
124
| – | – | ﹤0.01% | 6563 |
|
|
2021
Q3 | $2K | Hold |
124
| – | – | ﹤0.01% | 6333 |
|
|
2021
Q2 | $4K | Sell |
124
-3,624
| -97% | -$95.4K | ﹤0.01% | 6154 |
|
|
2021
Q1 | $83K | Sell |
3,748
-2,306
| -38% | -$52.8K | ﹤0.01% | 5419 |
|
|
2020
Q4 | $87K | Buy |
6,054
+4,851
| +403% | +$75.3K | ﹤0.01% | 5033 |
|
|
2020
Q3 | $19K | Buy |
1,203
+107
| +10% | +$1.95K | ﹤0.01% | 5159 |
|
|
2020
Q2 | $23K | Buy |
1,096
+127
| +13% | +$2.78K | ﹤0.01% | 5009 |
|
|
2020
Q1 | $18K | Sell |
969
-21
| -2% | -$535 | ﹤0.01% | 4972 |
|
|
2019
Q4 | $29K | Buy |
990
+2
| +0.2% | +$73 | ﹤0.01% | 5256 |
|
|
2019
Q3 | $50K | Buy |
988
+144
| +17% | +$8.51K | ﹤0.01% | 5177 |
|
|
2019
Q2 | $65K | Buy |
+844
| New | +$50.1K | ﹤0.01% | 5078 |
|
|
2018
Q4 | – | Hold |
0
| – | – | – | 5833 |
|
|
2018
Q3 | – | Hold |
0
| – | – | – | 5758 |
|
Other funds holding MRKR
JP Morgan Chase's MRKR Position: Q3 2026 in Review
JP Morgan Chase held its Marker Therapeutics (MRKR) position steady in Q3 2026 at 23 shares worth $25. The position accounts for ﹤0.01% of the portfolio, ranked #7963.
JP Morgan Chase first reported a position in MRKR in Q2 2019 and has held it in 30 quarters since. The position peaked at $87K in Q4 2020. 36 funds tracked by Wall St. Rank hold MRKR as of Q3 2026.
- JP Morgan Chase held 23 shares of Marker Therapeutics worth $25 as of Q3 2026.
- JP Morgan Chase left its Marker Therapeutics share count unchanged in Q3 2026.
- Marker Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q3 2026, its #7963 holding.
- JP Morgan Chase first reported a position in Marker Therapeutics in Q2 2019 and has held it in 30 quarters since.
- JP Morgan Chase's Marker Therapeutics position peaked at $87K in Q4 2020.
- 36 funds tracked by Wall St. Rank held Marker Therapeutics as of Q3 2026.
Based on JP Morgan Chase's 13F filing for Q3 2026, filed 12 Nov 2026.